[Malaria: a medical and economic problem].
Bourée
Patrice
P
D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use*; D000962:Antimalarials / Q000191:economics* / Q000627:therapeutic use*; D037621:Artemisinins / Q000191:economics* / Q000627:therapeutic use*; D053626:Atovaquone; D002738:Chloroquine / Q000191:economics* / Q000627:therapeutic use*; D004338:Drug Combinations; D004351:Drug Resistance; D004983:Ethanolamines / Q000191:economics* / Q000627:therapeutic use*; D005449:Fluorenes / Q000191:economics* / Q000627:therapeutic use*; D017048:Health Care Costs; D006801:Humans; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D009285:Naphthoquinones / Q000191:economics* / Q000627:therapeutic use*; D002727:Proguanil / Q000191:economics* / Q000627:therapeutic use*; D012717:Sesquiterpenes / Q000191:economics* / Q000627:therapeutic use*; D015996:Survival Rate; D014944:World Health Organization
D000890:Anti-Infective Agents; D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D009285:Naphthoquinones; D012717:Sesquiterpenes; C109496:atovaquone, proguanil drug combination; D002738:Chloroquine; C031327:artemisinin; D000078102:Lumefantrine; D002727:Proguanil; D053626:Atovaquone